Page 41 - TD-4-2

Tumor Discovery Understanding glioblastoma invasion and therapy

investigations into the ways human cancers are shaped by Institute. Data Source(s): SEER Incidence Data, November
the unique features of both central and peripheral nervous 2023 Submission (1975-2021), SEER 22 Registries; 2024.
tissue. 190 Available from: https://seer.cancer.gov/statistics-network/
explorer Last accessed on 2025 Apr 10].
Acknowledgments 5. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy
We wish to acknowledge an amazing scientist and mentor, plus concomitant and adjuvant temozolomide for
Dr. Arthur Alberts, who passed away from glioblastoma at glioblastoma. N Engl J Med. 2005;352(10):987-996.
the age of 52, as an inspiration for this review. doi: 10.1056/NEJMoa043330

Funding 6. Bauman GS, Gaspar LE, Fisher BJ, Halperin EC,
Macdonald DR, Cairncross JG. A prospective study of
Departmental funds from the Department of Cell and short-course radiotherapy in poor prognosis glioblastoma
Cancer Biology and the Department of Medical Education, multiforme. Int J Radiat Oncol Biol Phys. 1994;29(4):835-839.
College of Medicine and Life Sciences, University of doi: 10.1016/0360-3016(94)90573-8
Toledo, supported this work.
7. Whittle IR, Denholm SW, Gregor A. Management of patients
Conflict of interest aged over 60 years with supratentorial glioma: Lessons from
an audit. Surg Neurol. 1991;36(2):106-111.
The authors declare they have no competing interests. doi: 10.1016/0090-3019(91)90227-z
Author contributions 8. Parsons DW, Jones S, Zhang X, et al. An integrated genomic
analysis of human glioblastoma multiforme. Science.
Conceptualization: Kathryn N. Becker, Kathryn M. 2008;321(5897):1807-1812.
Eisenmann
Writing – original draft: Kathryn N. Becker doi: 10.1126/science.1164382
Writing – review & editing: All authors 9. Cancer Genome Atlas Research Network. Comprehensive
genomic characterization defines human glioblastoma genes
Ethics approval and consent to participate and core pathways. Nature. 2008;455(7216):1061-1068.
Not applicable. doi: 10.1038/nature07385
10. Neftel C, Laffy J, Filbin MG, et al. An integrative model of
Consent for publication cellular states, plasticity, and genetics for glioblastoma. Cell.
Not applicable. 2019;178(4):835-849.e21.
doi: 10.1016/j.cell.2019.06.024
Availability of data
11. U.S. Department of Health and Human Services - Rare
Not applicable. Cancers. U.S. Department of Health and Human Services.
2022. Available from: https://rarediseases.info.nih.gov/
References diseases/diseases-by-category/1/rare-cancers [Last accessed
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA on 2022 Jan 30].
Cancer J Clin. 2019;69(1):7-34. 12. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways
to glioblastoma: A population-based study. Cancer Res.
doi: 10.3322/caac.21551
2004;64(19):6892-6899.
2. Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS.
CBTRUS statistical report: Primary brain and other central doi: 10.1158/0008-5472.Can-04-1337
nervous system tumors diagnosed in the United States in 13. Ostrom QT, Egan KM, Nabors LB, et al. Glioma risk
2014-2018. Neuro Oncol. 2021;23(12 Suppl 2):iii1-iii105. associated with extent of estimated European genetic
ancestry in African Americans and Hispanics. Int J Cancer.
doi: 10.1093/neuonc/noab200
2020;146(3):739-748.
3. Hsu S, Quattrone M, Ostrom Q, Ryken TC, Sloan AE,
Barnholtz-Sloan JS. Incidence patterns for primary doi: 10.1002/ijc.32318
malignant spinal cord gliomas: A surveillance, epidemiology, 14. Porter AB, Lachance DH, Johnson DR. Socioeconomic
and end results study. J Neurosurg Spine. 2011;14(6):742-747. status and glioblastoma risk: A population-based analysis.
Cancer Causes Control. 2015;26(2):179-185.
doi: 10.3171/2011.1.SPINE10351
doi: 10.1007/s10552-014-0496-x
4. SEER*Explorer: An Interactive Website for SEER Cancer
Statistics. Surveillance Research Program, National Cancer 15. Braganza MZ, Kitahara CM, Berrington de González A,

Volume 4 Issue 2 (2025) 33 doi: 10.36922/td.8578